Odronextamab is an investigational CD20xCD3 bispecific antibody.
- Bladder, kidney, and other urologic cancers
- Bone and connective tissue cancer
- Breast cancer
- CNS cancers
- Colorectal and other GI cancers
- Cytoprotective and supportive care agents
- Eye cancer
- Gynecologic cancers
- Head and neck cancer
- Kaposi's sarcoma
- Leukemias, lymphomas, and other hematologic cancers
- Melanoma and other skin cancers
- Pancreatic, thyroid, and other endocrine cancers
- Prostate and other male cancers
- Respiratory and thoracic cancers
- Solid tumors
News and Features
The treatment was unlikely to demonstrate a survival benefit.
A new capsule dosage form has also been approved in 50mg and 100mg strengths.
Higher major pathological response seen for patients with resectable NSCLC treated with combo versus durvalumab alone.
Significantly higher rates of hyperglycemia seen for patients treated as standard care vs those in clinical trials.
The NETTER-2 trial included patients with newly diagnosed SSTR-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors.
Adding HIPEC to interval cytoreductive surgery improves long-term outcomes in stage III epithelial ovarian cancer, a phase 3 trial suggests.
The US supply of cisplatin is nearly restored, and shortages of carboplatin and methotrexate have been alleviated, the government says.
A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.
MWTX-003 is an investigational anti-TMPRSS6 designed to induce endogenous expression of hepcidin resulting in suppression of serum iron levels.
Urine albumin-creatinine ratio significantly higher for patients receiving dasatinib.
The sBLA was based on efficacy and safety data from the KEYNOTE-A18 trial.
Belzutifan is a hypoxia-inducible factor inhibitor.
Less than 30% of patients report comparing drug costs before selecting a Medicare Part D plan.
Ojjaara, a JAK inhibitor, is supplied as 100mg, 150mg, and 200mg tablets in 30 -count bottles.
Breakthroughs in targeted therapy and immunotherapy are partly responsible for the recent decline in US cancer deaths, according to the AACR Cancer Progress Report 2023.
Temozolomide is the second drug to receive a labeling update under Project Renewal.
Aphexda is expected to be available in September 2023.